On 12 May 2026, Celltrion announced that it has acquired a 100% stake in France-based healthcare firm, Gifrer. Gifrer operates more than 9,000 pharmacy sales channels and supply networks covering about 800 hospitals across France and will continue to operate independently post-acquisition.
The acquisition is aimed at strengthening Celltrion’s access to French pharmacy channels as France expands pharmacist-led biosimilar substitution. This includes anticipated approval for substitution of denosumab biosimilars later this year, with Celltrion planning to use Gifrer’s sales network to expand pharmacy sales for its denosumab biosimilars, Stoboclo® and Osenvelt®.
In addition, the acquisition expands Celltrion’s product portfolio beyond biopharmaceuticals, as Gifrer sells over 140 over-the-counter medicines and other health products. Celltrion expects the acquisition to generate an additional 250 billion won in revenue over the next 5 years.